Sakar Healthcare Signs Confidential Agreements with Three Indian Multinationals

Sakar Healthcare has announced the signing of confidential agreements with prominent Indian pharmaceutical companies, including Dr. Reddy's Laboratories, Biocon Pharma, and Emcure Pharmaceuticals.

These agreements focus on the development of API intermediates and finished dosage formulations (FDF) in the oncology sector. Sakar's EU GMP approved manufacturing unit will play a crucial role in the scale-up and production of oral solids and injections, aimed at enhancing the robustness of manufacturing processes and facilitating technology transfer for specialized FDFs.

Sakar will also align its technology-transfer processes to cater to niche finished dosage forms, while organizing its skill sets to deliver comprehensive solutions within the cytotoxic This strategic move is expected to strengthen Sakar's position as a trusted partner in oncology solutions for multinational pharmaceutical firms.

Get the announcement here

Sakar Healthcare 

Established in 2004, Sakar Healthcare specializes in manufacturing pharmaceutical products including liquid orals, cephalosporin tablets, capsules, dry powder syrups, injections, and lyophilized injections.

Operating as a Contract Development and Manufacturing Organization (CDMO), Sakar is EU GMP approved and serves leading multinational pharmaceutical companies. With state-of-the-art facilities certified by ISO 9001:2015, WHO-GMP, and other international standards.

 Sakar exports to over 50 countries across Africa, SEASIA, CIS, Latin & Central America, and Europe. The company is known for its commitment to quality and innovation in the global pharmaceutical industry, recently expanding its capabilities to include oncology finished dosage manufacturing with EU GMP approved units for both oral solids and injections.